These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 7711410)

  • 21. Mixed cryoglobulinemia type II in chronic hepatitis B associated with HBe-minus HBV mutant: cellular immune reactions and response to interferon treatment.
    Löhr H; Goergen B; Weber W; Gödderz W; Meyer zum Büschenfelde KH; Gerken G
    J Med Virol; 1994 Dec; 44(4):330-5. PubMed ID: 7897364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon alfa.
    Conjeevaram HS; Hoofnagle JH; Austin HA; Park Y; Fried MW; Di Bisceglie AM
    Gastroenterology; 1995 Aug; 109(2):540-6. PubMed ID: 7615204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chronic hepatitis B. Treatment in childhood with alpha-interferon].
    Wirth S; Sokal E; Schaefer E; Pohlenz J; Keller KM
    Monatsschr Kinderheilkd; 1992 Oct; 140(10):775-9. PubMed ID: 1435800
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Temporary HBV resolution in an HIV-coinfected patient during HBV-directed combination therapy followed by relapse of HBV.
    Wursthorn K; Buggisch P; Lutgehetmann M; Zollner B; Petersen J
    Antivir Ther; 2006; 11(5):647-52. PubMed ID: 16964835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proliferative response of CD4+ T cells and hepatitis B virus clearance in chronic hepatitis with or without hepatitis B e-minus hepatitis B virus mutants.
    Löhr HF; Weber W; Schlaak J; Goergen B; Meyer zum Buschenfelde KH; Gerken G
    Hepatology; 1995 Jul; 22(1):61-8. PubMed ID: 7601434
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, controlled trial of recombinant alpha-interferon therapy for chronic hepatitis B.
    Di Bisceglie AM; Fong TL; Fried MW; Swain MG; Baker B; Korenman J; Bergasa NV; Waggoner JG; Park Y; Hoofnagle JH
    Am J Gastroenterol; 1993 Nov; 88(11):1887-92. PubMed ID: 8237937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prospective randomized controlled trial of sequential treatment with corticoids and alpha-interferon versus treatment with interferon alone in patients with chronic active hepatitis B.
    Niederau C; Heintges T; Niederau M; Stremmel W; Strohmeyer G
    Eur J Med; 1992 Nov; 1(7):396-402. PubMed ID: 1341478
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interferon alfa for chronic active hepatitis B. Long term follow-up of 62 patients: outcomes and predictors of response.
    Hope RL; Weltman M; Dingley J; Fiatarone J; Hope AH; Craig PI; Grierson JM; Bilous M; Williams SJ; Farrell GC
    Med J Aust; 1995 Jan; 162(1):8-11. PubMed ID: 7845310
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus.
    Perrillo R; Tamburro C; Regenstein F; Balart L; Bodenheimer H; Silva M; Schiff E; Bodicky C; Miller B; Denham C
    Gastroenterology; 1995 Sep; 109(3):908-16. PubMed ID: 7657121
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon alfa-2b therapy in children with chronic hepatitis B.
    Sokal EM; Wirth S; Goyens P; Depreterre A; Cornu C
    Gut; 1993; 34(2 Suppl):S87-90. PubMed ID: 8314496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B.
    Hoofnagle JH; Peters M; Mullen KD; Jones DB; Rustgi V; Di Bisceglie A; Hallahan C; Park Y; Meschievitz C; Jones EA
    Gastroenterology; 1988 Nov; 95(5):1318-25. PubMed ID: 3049216
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy.
    Hsu CW; Yeh CT
    Hepatology; 2011 Jul; 54(1):101-8. PubMed ID: 21503942
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impaired response to alpha interferon in patients with an inapparent hepatitis B and hepatitis C virus coinfection.
    Zignego AL; Fontana R; Puliti S; Barbagli S; Monti M; Careccia G; Giannelli F; Giannini C; Buzzelli G; Brunetto MR; Bonino F; Gentilini P
    Arch Virol; 1997; 142(3):535-44. PubMed ID: 9349299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Problems in the management of chronic hepatitis B with interferon: experience in a randomized, multicentre study.
    Realdi G; Fattovich G; Pastore G; Caredda F; Noventa F; Santantonio T; Moroni M; Criscuolo D; Maladorno D; Rugge M
    J Hepatol; 1990; 11 Suppl 1():S129-32. PubMed ID: 2079570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Severe exacerbation of chronic hepatitis B following interferon therapy].
    Laskus T; Radkowski M; Cianciara J; Loch T; Slusarczyk J
    Wiad Lek; 1992 Jun; 45(11-12):458-61. PubMed ID: 1441531
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of hepatitis B-related polyarteritis nodosa with famciclovir and interferon alfa-2b.
    Kruger M; Böker KH; Zeidler H; Manns MP
    J Hepatol; 1997 Apr; 26(4):935-9. PubMed ID: 9126810
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon treatment of chronic active hepatitis B: effect of a six month treatment regimen.
    Raptopoulou M; Orphanou H; Vrettou H; Akribiadis E; Chadzikonstantinou L; Goulis G
    Gut; 1993; 34(2 Suppl):S102-3. PubMed ID: 8314469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial.
    Bourlière M; Rabiega P; Ganne-Carrie N; Serfaty L; Marcellin P; Barthe Y; Thabut D; Guyader D; Hezode C; Picon M; Causse X; Leroy V; Bronowicki JP; Carrieri P; Riachi G; Rosa I; Attali P; Molina JM; Bacq Y; Tran A; Grangé JD; Zoulim F; Fontaine H; Alric L; Bertucci I; Bouvier-Alias M; Carrat F;
    Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):177-188. PubMed ID: 28404133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.